Thursday, August 22, 2013
Institute Pasteur Korea, a branch of France's Pasteur Institute
primarily financed by the government of South Korea, is starting to see
translatable results from its partnering and drug screening efforts. Institute
Pasteur Korea recently announced its third deal of the year, licensing a tuberculosis
candidate to Qurient Co. Ltd.,
an institute spinout.1
L. SciBX 6(32);
doi:10.1038/scibx.2013.847 Published online Aug. 22, 2013
1. Pethe, K. et al.
Nat. Med.; published online Aug. 4, 2013; doi:10.1038/nm.3262 Contact:
Kevin Pethe, Institute Pasteur Korea, Seongnam-si, South Korea e-mail: email@example.com
Atinum Investment Co. Ltd. (KOSDAQ:021080), Seoul, South Korea
Global Alliance for TB Drug Development, New York, N.Y.
Hanwha Investment Corp., Seoul, South Korea
Institute Pasteur Korea, Seongnam-si, South Korea
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Novartis Venture Funds, Basel, Switzerland
Pasteur Institute, Paris, France
Qurient Co. Ltd., Seongnam-si, South Korea
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
(Euronext:SAN; NYSE:SNY), Paris, France